Macrocyclic isoquinoline peptide inhibitors of hepatitis C...

Details Macrocyclic isoquinoline peptide inhibitors of hepatitis C... Macrocyclic isoquinoline peptide inhibitors of hepatitis C...

2007-02-06

2007-02-06

Campell, Bruce R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

10825693

ABSTRACT:
Macrocyclic isoquinoline peptides are disclosed having the general formula:A compound of formula I:wherein R1to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

REFERENCES:
patent: 6534523 (2003-03-01), Llinas-Brunet et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 2004/0038872 (2004-02-01), Campbell et al.
patent: WO 00/59929 (2000-10-01), None
Lauer, Georg M. et al., “Hepatitis C Virus Infection”, New England Journal of Medicine, vol. 345, No. 1, pp. 41-52 (2001).
Poynard, Thierry et al., “Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus”, The Lancet, vol. 352, pp. 14226-1432, (1998).
Zeuzem, Stefan et al., “Peginterferon Alfa-2a in Patents with Chronic Hepatitis C”, New England Journal of Medicine, vol. 343, pp. 1666-1672, (2000).

Affiliated with

Also associated with

Rating

Macrocyclic isoquinoline peptide inhibitors of hepatitis C... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Macrocyclic isoquinoline peptide inhibitors of hepatitis C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic isoquinoline peptide inhibitors of hepatitis C... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3874695